恩替卡韦对慢性乙型肝炎患者Th17/Treg型细胞因子影响的研究进展  

Advances study on the effect of entecavir on Th17/Treg cytokines for patients with chronic hepatitis B

作　　者：古雪[1] 王川林[1] 刘娇[1] 梅怡晗 李铃[1] 朱其荣[1] GU Xue;WANG Chuan-lin;LIU Jiao;MEI Yi-han;LI Ling;ZHU Qi-rong(Department of Infectious Disease, Affiliated Hospital of North Sichuan Medical College ,Nanchong 631000 , Sichuan;The Capital Medical University,Beijing 100069 , China)

机构地区：[1]川北医学院附属医院感染科,四川南充637000 [2]首都医科大学,北京610041

出　　处：《川北医学院学报》2017年第4期632-637,共6页Journal of North Sichuan Medical College

摘　　要：世界卫生组织报告全球约有20亿人曾感染乙肝病毒(HBV),其中2.4亿人为慢性HBV感染者,每年约有65万人死于HBV感染所致的肝功能衰竭、肝硬化和肝细胞癌。在乙型肝炎患者中,HBV持续存在和复制与机体细胞免疫作用密切相关,其结果将导致肝组织炎症持续、反复或慢性化,甚至发展为肝硬化、肝癌。而CD4+T细胞在其细胞免疫作用机制中起到了核心作用,其中CD4+T细胞的两个重要细胞亚群,Th17/Treg型细胞所分泌的主要细胞因子IL-17、IL-21、IL-35、TGF-β、IL-10等在其炎症反应、抗感染免疫、组织细胞浸润等方面起到了重要作用。恩替卡韦作为慢性乙型肝炎抗病毒治疗的主要用药,它在抑制HBV复制,改善生化指标和组织学等方面有了较大进展,对慢性乙型肝炎治疗方面显示出了较大的潜力,但目前关于恩替卡韦对慢性乙型肝炎患者外周血清Th17/Treg型细胞因子影响的报道较少,本文就恩替卡韦在慢性乙型肝炎抗病毒治疗中对Th17/Treg型细胞因子影响的研究进展进行综述。The world health organization report about2billion people worldwide had HBV infection,including240million peo-pie with chronic HBV infection,about650thousand people die each year from liver failure caused by HBV infection,liver cirrhosis and hepatocellular carcinoma(HCC).In hepatitis B patients,and the persistence of HBV replication was closely related to the cellular im-mune function,the result would lead to inflammation of the liver tissue,repeated or chronic continuously,even for the development of liver cirrhosis,liver cancer.And CD4+T cells in its cellular immune mechanism had played a central role,including CD4+T cells of two important cells,type of Thl7/Treg cells produce cytokines IL-17,IL-21,IL-35,TGF-(3,IL-10in the inflammatory response,anti-infec-tion immunity,tissue infiltration,etc played an important role.Entecavir as the main drug of chronic hepatitis B antiviral treatment,it,s in inhibition of HBV replication,improve the biochemical indices and histological aspects and so on had great progress,for the treatment of chronic hepatitis B had showed great potential,but currently on entecavir in patients with chronic hepatitis B clear type of Thl7/Treg cells in peripheral blood factor influence,the reports in this paper,the entecavir in chronic hepatitis B antiviral treatment on the effect of the type of Thl7/Treg cells factor research progress were summarized.

关 键 词：恩替卡韦 THL7细胞 Trg细胞 细胞因子 

分 类 号：R512.62[医药卫生—内科学]